Fiche centre
Mount Sinai Hospital
New York — United States
Essais liés18clinical trials
VilleNew Yorklocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05673148
Essais cliniques associés
18| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Tricuspid Transcatheter Edge-to-Edge Repair (TEER) | Maladie coronarienne | À vérifier | NCT07586995 | TREAT TR — A Post-Market Assessment of the Safety and Performance of the TriClip™ System | RECRUITING |
| buntanetap/posiphen | Parkinson | Phase 2/3 | NCT07284784 | A Study of Buntanetap in Participants With PD | RECRUITING |
| Stentrode | Sclérose latérale amyotrophique | Non applicable | NCT07543367 | INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study | ACTIVE_NOT_RECRUITING |
| Bevacizumab | Cancer | Phase 3 | NCT07198074 | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | RECRUITING |
| InnAVasc Arteriovenous Graft (IG) surgical implant | Maladie rénale chronique | Non applicable | NCT04671771 | A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | RECRUITING |
| Stereotactic Ablative Radiotherapy | Cancer | Phase 2 | NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06058377 | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | RECRUITING |
| Azacitidine | Cancer | Phase 2 | NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | RECRUITING |
| RNS System | Épilepsie | Phase 2 | NCT05339126 | RNS System LGS Feasibility Study | ACTIVE_NOT_RECRUITING |
| Ketamine Hydrochloride | Épilepsie | Phase 2 | NCT05019885 | The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy | COMPLETED |
| Biopsy Procedure | Cancer | Phase 1/2 | NCT04172532 | Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | RECRUITING |
| Cenobamate | Épilepsie | Phase 4 | NCT06453213 | Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Acoramidis | Alzheimer | Phase 3 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | RECRUITING |
| Anastrozole | Cancer | Phase 3 | NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | RECRUITING |
| Bevacizumab | Cancer | Phase 2 | NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | COMPLETED |